Encouraging H2 supports a positive outlook
For the year to 30 April 2023 Kromek reported revenue of £17.3m, +44%YoY, and an EBITDA (adj.) loss of £1.0m. The salient feature was the reversal of the H1 (adj.) EBITDA loss of £2.61m to a H2 (adj.) EBITDA profit of £1.63m. Gross profitability also improved, from a 46.8% margin in FY22 to 51.6%, again with a strong H2 improvement at a 59.3% margin. The year-end cash position was £1.1m then post year-end the Group raised £8.0m to fund growth prospects.We estimate FY23 revenue in the Advanced Imaging division of £7.6m +65%YoY, and in the CBRN segment, £7.4m, +38%YoY. Importantly the balance of revenue generation continued to shift towards Products, comprising 85% of total (FY22: 82%), rather than R&D-related projects.
On 18 April Kromek announced a major 7 year agreement with a Tier 1 OEM to develop and incorporate its CZT-based detectors in advanced medical imaging scanners. We base our outlook on the assumption that the Tier 1 OEM agreement addresses the CT scanner market estimated to be worth c.US$10bn by 20291; and see Kromek potentially adding over £100m to revenue by 2029.
We make no changes to our FY24 outlook, and introduce FY25 forecasts: with estimated revenue of £25.1m and EBITDA of £2.6m indicative of an EV/EBITDA multiple of 6x
Our Fair Value is also maintained at 26p/share.
Kromek Group is a developer of radiation detectors based on cadmium zinc telluride, providing detection and characterization capabilities within the medical imaging, nuclear detection and security screening markets. Co. designs, develops and produces x-ray and gamma-ray imaging and radiation detection products.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.